← Every firm
QuVa Pharma, Inc. FDA Recalls
6 recalls on file across drugs, 0 of them Class I and 5 still open. This firm is not matched to a listed company.
Newest first
Class I is the FDA's most serious grade: a reasonable probability of serious harm or death.
| Product |
|---|
| Methohexital Sodium, 100 mg/10 mL (10 mg/mL), Total Volume: 10 mL, Rx only, Compounded drug, QuVa Pharma, 1075 W Park OnClass IIJun 24, 2026Failed Impurities/Degradation Specifications |
| R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chloride Solution, Total VoClass IIOct 10, 2025Presence of Particulate Matter |
| fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.1% Bupivacaine HCl 100 mg/100 mL (1 mg/mL), 100 ml in NS Yellow CADD FSClass IIMar 6, 2025Lack of Assurance of Sterility |
| fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.125% Bupivacaine HCl 125 mg/100 mL (1.25 mg/mL), 100 ml in NS Yellow CAClass IIMar 6, 2025Lack of Assurance of Sterility |
| fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.2% ROPivacaine HCl 200 mg/100 mL (2 mg/mL), 100 ml in NS Yellow CADD FSClass IIMar 6, 2025Lack of Assurance of Sterility |
| oxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium Chloride, Injection for IV Use, High Alert, This is a CompClass IIISep 20, 2022Incorrect Product Formulation: Oxytocin 30 units was added t |